Cargando…

Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up

INTRODUCTION: The chromosome 22q11.2 deletion syndrome comprises phenotypically similar diseases characterized by abnormal development of the third and fourth branchial arches, resulting in variable combinations of congenital heart defects, dysmorphisms, hypocalcemia, palatal dysfunction, developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarli, Walter Maria, Ricci, Silvia, Lodi, Lorenzo, Cavone, Federica, Pacillo, Lucia, Giancotta, Carmela, Ubertini, Graziamaria, Baroncelli, Giampiero, Cancrini, Caterina, Azzari, Chiara, Stagi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450035/
https://www.ncbi.nlm.nih.gov/pubmed/37635986
http://dx.doi.org/10.3389/fendo.2023.1209577
_version_ 1785095103508905984
author Sarli, Walter Maria
Ricci, Silvia
Lodi, Lorenzo
Cavone, Federica
Pacillo, Lucia
Giancotta, Carmela
Ubertini, Graziamaria
Baroncelli, Giampiero
Cancrini, Caterina
Azzari, Chiara
Stagi, Stefano
author_facet Sarli, Walter Maria
Ricci, Silvia
Lodi, Lorenzo
Cavone, Federica
Pacillo, Lucia
Giancotta, Carmela
Ubertini, Graziamaria
Baroncelli, Giampiero
Cancrini, Caterina
Azzari, Chiara
Stagi, Stefano
author_sort Sarli, Walter Maria
collection PubMed
description INTRODUCTION: The chromosome 22q11.2 deletion syndrome comprises phenotypically similar diseases characterized by abnormal development of the third and fourth branchial arches, resulting in variable combinations of congenital heart defects, dysmorphisms, hypocalcemia, palatal dysfunction, developmental or neuropsychiatric disorders, and impairment of the immune system due to thymic dysfunction. Other genetic syndromes, often called DiGeorge-like, share clinical and immunological features with 22q11.2 deletion syndrome. This syndrome has been rarely associated with malignancies, mainly hematological but also hepatic, renal, and cerebral. Rarely, malignancies in the head and neck region have been described, although no aggregate of data on the development of thyroid neoplasms in patients with this clinical phenotype has been conducted so far. MATERIALS AND METHODS: To characterize this possible association, a multicenter survey was made. Thus, we present a case series of five pediatric patients with 22q11.2 deletion syndrome or DiGeorge-like syndrome who were occasionally found with confirmed or highly suspected neoplasms of the thyroid gland during their follow-up. In three cases, malignancies were histologically confirmed, but their outcome was good due to an early recognition of suspicious nodules and precocious surgery. CONCLUSIONS: This study underlines for clinicians the higher risk of neoplasms in the head and neck district for patients affected by these syndromes. It also emphasizes the importance of a prolonged clinical and ultrasound follow-up for patients with this clinical and immunological phenotype.
format Online
Article
Text
id pubmed-10450035
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104500352023-08-26 Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up Sarli, Walter Maria Ricci, Silvia Lodi, Lorenzo Cavone, Federica Pacillo, Lucia Giancotta, Carmela Ubertini, Graziamaria Baroncelli, Giampiero Cancrini, Caterina Azzari, Chiara Stagi, Stefano Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: The chromosome 22q11.2 deletion syndrome comprises phenotypically similar diseases characterized by abnormal development of the third and fourth branchial arches, resulting in variable combinations of congenital heart defects, dysmorphisms, hypocalcemia, palatal dysfunction, developmental or neuropsychiatric disorders, and impairment of the immune system due to thymic dysfunction. Other genetic syndromes, often called DiGeorge-like, share clinical and immunological features with 22q11.2 deletion syndrome. This syndrome has been rarely associated with malignancies, mainly hematological but also hepatic, renal, and cerebral. Rarely, malignancies in the head and neck region have been described, although no aggregate of data on the development of thyroid neoplasms in patients with this clinical phenotype has been conducted so far. MATERIALS AND METHODS: To characterize this possible association, a multicenter survey was made. Thus, we present a case series of five pediatric patients with 22q11.2 deletion syndrome or DiGeorge-like syndrome who were occasionally found with confirmed or highly suspected neoplasms of the thyroid gland during their follow-up. In three cases, malignancies were histologically confirmed, but their outcome was good due to an early recognition of suspicious nodules and precocious surgery. CONCLUSIONS: This study underlines for clinicians the higher risk of neoplasms in the head and neck district for patients affected by these syndromes. It also emphasizes the importance of a prolonged clinical and ultrasound follow-up for patients with this clinical and immunological phenotype. Frontiers Media S.A. 2023-08-10 /pmc/articles/PMC10450035/ /pubmed/37635986 http://dx.doi.org/10.3389/fendo.2023.1209577 Text en Copyright © 2023 Sarli, Ricci, Lodi, Cavone, Pacillo, Giancotta, Ubertini, Baroncelli, Cancrini, Azzari and Stagi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Sarli, Walter Maria
Ricci, Silvia
Lodi, Lorenzo
Cavone, Federica
Pacillo, Lucia
Giancotta, Carmela
Ubertini, Graziamaria
Baroncelli, Giampiero
Cancrini, Caterina
Azzari, Chiara
Stagi, Stefano
Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title_full Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title_fullStr Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title_full_unstemmed Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title_short Risk of thyroid neoplasms in patients with 22q11.2 deletion and DiGeorge-like syndromes: an insight for follow-up
title_sort risk of thyroid neoplasms in patients with 22q11.2 deletion and digeorge-like syndromes: an insight for follow-up
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450035/
https://www.ncbi.nlm.nih.gov/pubmed/37635986
http://dx.doi.org/10.3389/fendo.2023.1209577
work_keys_str_mv AT sarliwaltermaria riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT riccisilvia riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT lodilorenzo riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT cavonefederica riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT pacillolucia riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT giancottacarmela riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT ubertinigraziamaria riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT baroncelligiampiero riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT cancrinicaterina riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT azzarichiara riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup
AT stagistefano riskofthyroidneoplasmsinpatientswith22q112deletionanddigeorgelikesyndromesaninsightforfollowup